Characterization of Aspergillus fumigatus specific CD4 T cell responses.

烟曲霉特异性 CD4 T 细胞反应的表征。

基本信息

  • 批准号:
    7171873
  • 负责人:
  • 金额:
    $ 44.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-02-01 至 2011-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Aspergillus fumigatus is a spore forming mold that causes a range of human diseases, including allergic bronchopulmonary aspergillosis, an asthma-like disease, and invasive aspergillosis, a frequently fatal infection that occurs in immunocompromised individuals. Infection by Aspergillus fumigatus results from inhalation of fungal spores (referred to as conidia), which are taken up by alveolar macrophages and killed by products of the oxidative burst. Although A. fumigatus-specific T lymphocytes are postulated to play a role in both allergic and invasive aspergillosis, very little is known about their activation, proliferation, differentiation and persistence following inhalation of fungal spores. To address this issue, we made CD4 T cell hybridomas specific for A. fumigatus antigens, cloned the alpha and beta chains of the specific T cell receptor and generated T cell receptor transgenic mice. Experiments proposed in this grant application will use T cell receptor transgenic mice to obtain naive, A. fumigatus-specific T cells for transfer and characterization in infected recipient mice. We have three specific aims. The first is to investigate priming and differentiation of naive A. fumigatus-specific T lymphocytes following pulmonary infection with live conidia. The impact of IL10 and TGF-beta signaling on T cell proliferation and differentiation will be determined. The second aim is to determine the impact of A. fumigatus-specific CD4 T cells on invasive fungal disease in immunocompromised or bone marrow transplanted mice. Our third aim is to investigate innate immune responses to fungal spores and to determine the impact of this process on the differentiation of A. fumigatus-specific CD4 T cells. We will initially focus on MyD88, Trif and Rip2 mediated signals. These studies will provide a comprehensive picture of T cell responses to the most prevalent opportunistic fungal pathogen of humans, potentially opening the door to new therapeutic interventions to combat allergic and invasive fungal diseases.
描述(由申请人提供):烟曲霉是一种孢子形成霉菌,可导致一系列人类疾病,包括过敏性支气管肺曲霉菌病,一种哮喘样疾病,以及侵袭性曲霉病,一种经常发生在免疫功能低下的人身上的致命感染。感染烟曲霉菌的原因是吸入了真菌孢子(称为分生孢子),分生孢子被肺泡巨噬细胞摄取,并被氧化爆发的产物杀死。尽管烟曲霉菌特异性T淋巴细胞在过敏性和侵袭性曲霉病中都起作用,但对其在吸入真菌孢子后的激活、增殖、分化和持久性了解甚少。为了解决这个问题,我们制作了针对烟曲霉菌抗原的CD4T细胞杂交瘤,克隆了特异性T细胞受体的α链和β链,并产生了T细胞受体转基因小鼠。在这项拨款申请中提出的实验将使用T细胞受体转基因小鼠来获得幼稚的、烟曲霉菌特异的T细胞,用于在受感染的小鼠中转移和鉴定。我们有三个具体目标。第一个是研究活孢子肺部感染后幼稚烟曲霉菌特异性T淋巴细胞的启动和分化。IL-10和转化生长因子-β信号对T细胞增殖和分化的影响将被确定。第二个目的是确定烟曲霉特异的CD4T细胞对免疫受损或骨髓移植小鼠侵袭性真菌疾病的影响。我们的第三个目标是研究对真菌孢子的先天免疫反应,并确定这一过程对烟曲霉特异性CD4T细胞分化的影响。我们将首先关注MyD88、Trif和RIP2介导的信号。这些研究将提供T细胞对人类最普遍的机会性真菌病原体的反应的全面图景,可能为对抗过敏性和侵袭性真菌疾病的新的治疗干预打开大门。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric G. Pamer其他文献

Expression and deletion analysis of the Trypanosoma brucei rhodesiense cysteine protease in Escherichia coli
布氏罗得西亚锥虫半胱氨酸蛋白酶在大肠杆菌中的表达及缺失分析
  • DOI:
  • 发表时间:
    1991
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Eric G. Pamer;C. Davis;Magdalene So
  • 通讯作者:
    Magdalene So
Gut microbes fend off harmful bacteria by depriving them of nutrients
肠道微生物通过剥夺有害细菌的营养物质来抵御它们。
  • DOI:
    10.1038/d41586-024-02803-w
  • 发表时间:
    2024-09-18
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Eric G. Pamer
  • 通讯作者:
    Eric G. Pamer
Protection against emClostridioides difficile/em disease by a naturally avirulent strain
天然无毒菌株对艰难梭菌疾病的保护作用
  • DOI:
    10.1016/j.chom.2024.11.003
  • 发表时间:
    2025-01-08
  • 期刊:
  • 影响因子:
    18.700
  • 作者:
    Qiwen Dong;Stephen Harper;Emma McSpadden;Sophie S. Son;Marie-Maude Allen;Huaiying Lin;Rita C. Smith;Carolyn Metcalfe;Victoria Burgo;Che Woodson;Anitha Sundararajan;Amber Rose;Mary McMillin;David Moran;Jessica Little;Michael W. Mullowney;Ashley M. Sidebottom;Louis-Charles Fortier;Aimee Shen;Eric G. Pamer
  • 通讯作者:
    Eric G. Pamer
Immune Responses to <em>Aspergillus fumigatus</em> Infections
  • DOI:
    10.1016/j.bbmt.2005.09.007
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Amariliz Rivera;Tobias Hohl;Eric G. Pamer
  • 通讯作者:
    Eric G. Pamer
A spoonful of sugar could be the medicine
一勺糖可能就是良药
  • DOI:
    10.1038/nature23084
  • 发表时间:
    2017-06-14
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Hea-Jin Jung;Eric G. Pamer
  • 通讯作者:
    Eric G. Pamer

Eric G. Pamer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric G. Pamer', 18)}}的其他基金

CACHET - Environmental Biomarkers Core
CACHET - 环境生物标志物核心
  • 批准号:
    10641975
  • 财政年份:
    2017
  • 资助金额:
    $ 44.33万
  • 项目类别:
CACHET - Environmental Biomarkers Core
CACHET - 环境生物标志物核心
  • 批准号:
    10394644
  • 财政年份:
    2017
  • 资助金额:
    $ 44.33万
  • 项目类别:
Systems Biology of Microbiome-mediated Resilience to Antibiotic-resistant Pathogens
微生物组介导的对抗生素耐药病原体的恢复力的系统生物学
  • 批准号:
    9922844
  • 财政年份:
    2016
  • 资助金额:
    $ 44.33万
  • 项目类别:
Systems Biology of Microbiome-mediated Resilience to Antibiotic-resistant Pathogens
微生物组介导的对抗生素耐药病原体的恢复力的系统生物学
  • 批准号:
    9108539
  • 财政年份:
    2016
  • 资助金额:
    $ 44.33万
  • 项目类别:
Systems Biology of Microbiome-mediated Resilience to Antibiotic-resistant Pathogens
微生物组介导的对抗生素耐药病原体的恢复力的系统生物学
  • 批准号:
    9234463
  • 财政年份:
    2016
  • 资助金额:
    $ 44.33万
  • 项目类别:
Innate immune defense against clostridium Difficile Infection
针对艰难梭菌感染的先天免疫防御
  • 批准号:
    9175987
  • 财政年份:
    2012
  • 资助金额:
    $ 44.33万
  • 项目类别:
Innate Immune Defense against Clostridium Difficile Infection
针对艰难梭菌感染的先天免疫防御
  • 批准号:
    8871670
  • 财政年份:
    2012
  • 资助金额:
    $ 44.33万
  • 项目类别:
Innate immune defense against clostridium Difficile Infection
针对艰难梭菌感染的先天免疫防御
  • 批准号:
    10055905
  • 财政年份:
    2012
  • 资助金额:
    $ 44.33万
  • 项目类别:
Innate Immune Defense against Clostridium Difficile Infection
针对艰难梭菌感染的先天免疫防御
  • 批准号:
    8683090
  • 财政年份:
    2012
  • 资助金额:
    $ 44.33万
  • 项目类别:
Innate Immune Defense against Clostridium Difficile Infection
针对艰难梭菌感染的先天免疫防御
  • 批准号:
    8369912
  • 财政年份:
    2012
  • 资助金额:
    $ 44.33万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 44.33万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 44.33万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 44.33万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 44.33万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 44.33万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 44.33万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 44.33万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 44.33万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 44.33万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 44.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了